CTMX 241115 6.00P (CTMX241115P6000) Stock Options, News & Quotes

Account Info

Log Out

US OptionsDetailed Quotes

CTMX241115P6000

Watchlist

0.00
0.000.00%

15min DelayClose Oct 30 09:30 ET

0.00High0.00Low

Intraday

5D
Daily

No Data

News

Express News | CytomX Therapeutics Announces First Patient Dosed With Cx-801, a Dually-Masked Interferon-Alpha 2B Probody®, in a Phase 1 Study in Patients With Solid Tumors
ReutersSep 9 08:00 ET
CytomX Therapeutics Announces First Patient Dosed With CX-801, a Dually-Masked Interferon-Alpha 2b PROBODY, in a Phase 1 Study in Patients With Solid Tumors
Yahoo FinanceSep 9 08:00 ET
CytomX Therapeutics to Present at Upcoming September Investor Conferences
GlobeNewswireSep 4 08:00 ET
Analysts Offer Insights on Healthcare Companies: BioCardia (BCDA) and CytomX Therapeutics (CTMX)
TipRanksAug 22 09:20 ET · Ratings
HC Wainwright & Co. Reiterates Neutral on CytomX Therapeutics
BenzingaAug 22 07:31 ET
CytomX Therapeutics Analyst Ratings
BenzingaAug 22 07:30 ET · Ratings

Comments

Bigmoney Dreamer

Oct 11 00:26

$CytomX (CTMX.US)$ might be 8 Xbagger you never know 🤷🏻‍♂️

Jaguar8

Sep 9 07:02

NEWS

$CytomX (CTMX.US)$
CytomX Therapeutics Announces First Patient Dosed with CX-801, a Dually-Masked Interferon-Alpha 2b PROBODY®, in a Phase 1 Study in Patients with Solid Tumors

102979232

Jul 12 18:47

$CytomX (CTMX.US)$ Volumn is very low but rising slowly. Interesting

amiable Hedgehog_758

May 13 05:27

$CytomX (CTMX.US)$ what is going on with this stock amy one know ?

Stock Region

May 9 13:31

Therapeutics Company Reveals Positive Data From Cancer Clinical Study

CX-904 showcased a favorable safety profile, a critical factor in the administration and monitoring of patients in outpatient settings.
CytomX Therapeutics, Inc. (Nasdaq: CTMX) unveiled positive initial data from its ongoing CX-904 Phase 1a dose escalation clinical study. This pivotal study is centered around CX-904, an investigational PROBODY® T-cell engager that is both masked and conditionally activated, designed to target t...